Publication:
Thyroid lobectomy in patients with differentiated thyroid cancer: an analysis of the clinical outcomes in a nationwide multicenter study.

dc.contributor.authorDíez, Juan J
dc.contributor.authorAlcázar, Victoria
dc.contributor.authorIglesias, Pedro
dc.contributor.authorRomero-Lluch, Ana
dc.contributor.authorSastre, Julia
dc.contributor.authorCorral, Begoña Pérez
dc.contributor.authorZafón, Carles
dc.contributor.authorGalofré, Juan Carlos
dc.contributor.authorPamplona, María José
dc.date.accessioned2023-02-09T10:45:34Z
dc.date.available2023-02-09T10:45:34Z
dc.date.issued2021
dc.description.abstractTotal thyroidectomy is the standard initial surgery for differentiated thyroid carcinoma (DTC), but the extent of the thyroidectomy remains controversial. Thyroid lobectomy (TL) has been widely used in eastern countries; however, its use has not been generalized in western countries, including Spain. Our aims were to analyse the clinical outcome of a multicentre nation-wide cohort of DTC patients treated by TL and to assess the proportion of patients who required completion of the thyroidectomy and who presented disease recurrence. We retrospectively analyzed patients who underwent TL for DTC and were followed-up for ≥12 months. We collected demographic, clinical, and histopathological data. Dynamic risk stratification (DRS) was performed at 12 months and at last visit. One hundred and sixty-four patients (128 women, mean age 50.8 years, median follow-up 45.4 months) from 9 hospitals were included. There were 158 cases of papillary and 6 of follicular thyroid carcinoma (FTC). Remission of the disease (excellent response) was shown in 71.6% of the patients at 12 months and in 74.4% at the end of follow-up. At that time, there were 34 patients (20.7%) with indeterminate response, 6 (3.7%) with biochemical incomplete response, and 2 (1.2%) with structural incomplete response. Completion of the thyroidectomy was necessary in 8 patients (4.9%), but only 3 of them (1.8%) had disease recurrence. These results, obtained in real clinical practice, suggest that TL is a safe operative option for selected patients with DTC and that the intensity of the treatment must be tailored according to the presurgical tumor-associated risk, in line with a personalized medicine.
dc.identifier.doi10.21037/gs-20-712
dc.identifier.issn2227-684X
dc.identifier.pmcPMC7944057
dc.identifier.pmid33708550
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944057/pdf
dc.identifier.unpaywallURLhttps://gs.amegroups.com/article/viewFile/58020/pdf
dc.identifier.urihttp://hdl.handle.net/10668/17338
dc.issue.number2
dc.journal.titleGland surgery
dc.journal.titleabbreviationGland Surg
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number678-689
dc.pubmedtypeJournal Article
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectDifferentiated thyroid carcinoma (DTC)
dc.subjectdynamic risk stratification (DRS)
dc.subjectlobectomy
dc.subjectthyroid surgery
dc.subjecttumor recurrence
dc.titleThyroid lobectomy in patients with differentiated thyroid cancer: an analysis of the clinical outcomes in a nationwide multicenter study.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number10
dspace.entity.typePublication

Files